医学
肺癌
中枢神经系统
疾病
癌症
药品
抗体-药物偶联物
抗体
癌症研究
肿瘤科
免疫学
单克隆抗体
内科学
药理学
作者
David J. H. Bian,Sara Frida Cohen,Anna-Maria Lazaratos,Nathaniel Bouganim,Matthew Dankner
标识
DOI:10.3390/curroncol31100471
摘要
Antibody–drug conjugates (ADCs) represent an emerging class of targeted anticancer agents that have demonstrated impressive efficacy in numerous cancer types. In non-small cell lung cancer (NSCLC), ADCs have become a component of the treatment armamentarium for a subset of patients with metastatic disease. Emerging data suggest that some ADCs exhibit impressive activity even in central nervous system (CNS) metastases, a disease site that is difficult to treat and associated with poor prognosis. Herein, we describe and summarize the existing evidence surrounding ADCs in NSCLC with a focus on CNS activity.
科研通智能强力驱动
Strongly Powered by AbleSci AI